rafal_olechowski
- Centogene (NASDAQ:CNTG) announced Tuesday it extended a collaboration with Takeda Pharmaceutical (NYSE:TAK) to diagnose patients with Lysosomal Storage Disorders (LSDs), a group of inherited metabolic diseases.
- Per the terms, the German biotech will continue to provide its testing solutions to Takeda (TAK) for the early and rapid diagnosis of patients with LSDs such as Fabry disease, Gaucher disease, and Hunter syndrome.
- “Extending our longstanding partnership with Takeda highlights the continuing need to accelerate diagnoses for LSD patients globally and the ability of CENTOGENE to fulfill this vital service,” Centogene’s (CNTG) commercial chief Ian Rentsch remarked.
- The announcement marks the latest renewal of a deal CNTG first established in 2015 with Shire Pharmaceuticals, which the Japanese pharma giant acquired for $62B in 2019.
More on Centogene, Takeda, etc.
- Takeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwinds
- Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits
- Takeda Pharmaceutical Company Limited 2023 Q3 - Results - Earnings Call Presentation
- Takeda buoyed by mid-stage trial for immune disorder treatment mezagitamab
- Pfizer succeeds in Phase 3 trial for Adcetris in new lymphoma condition